Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates - Rapport Therapeutics (NASDAQ:RAPP)

Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates - Rapport Therapeutics (NASDAQ:RAPP)

BOSTON and SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today will host its inaugural Investor and Analyst Day, featuring presentations from Rapport's executive team on the Company's strategic prioriti…

# Hope on the Horizon Rapport Therapeutics Completes Enrollment in Landmark Trial for Refractory Focal Epilepsy Treat...

In a recent Investor and Analyst Day, Rapport Therapeutics made noteworthy strides in its ongoing commitment to advancing treatments for neurological disorders, particularly refractory focal epilepsy. The company announced that it has successfully enrolled all participants in its Phase 2a clinical trial of RAP219, a novel therapeutic candidate aimed at addressing this challenging condition. With patient recruitment now complete, Rapport is poise…